Verastem Oncology shares increased by 10.6% on August 8, 2025, compared to the S&P 500's 7.9% gain.
2 reports, 2 independent
Updated Aug 8
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Verastem Oncology shares increased by 10.6% on August 8, 2025, compared to the S&P 500's 7.9% gain.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Verastem Oncology
Pharmaceutical company in Masachussets, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksVerastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates Verastem (VSTM) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to a
- Clinical Trials ArenaVerastem’s avutometinib combination shows 31% ORR in ovarian cancer trial Verastem Oncology has reported primary analysis data from the two-part multicentre Phase II RAMP 201 trial, demonstrating tha